Twist Bioscience Corporation (TWST)

Twist Bioscience Announces Fiscal 2026 Second Quarter Financial ResultsMay 4, 2026 7:15 AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the second quarter fiscal 2026 ended March 31, 2026.


Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal second quarter 2026 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations.


The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company’s business. The conference call will be webcast live through the Investor Relations section under the “Company” tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.


About Twist Bioscience Corporation


At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets.


We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal – more experiments, more iterations, more chances for remarkable discoveries.


Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all. For more information about our products and services, please visit www.twistbioscience.com.


Follow us on LinkedIn | X | YouTube | Instagram | Bluesky

View source version on businesswire.com: https://www.businesswire.com/news/home/20260504943777/en/
For Investors:

Angela Bitting

SVP, Corporate Affairs

925-202-6211

abitting@twistbioscience.com


For Media:

Amanda Houlihan

Communications Manager

774-265-5334

ahoulihan@twistbioscience.com


Original: Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex SequencesMay 4, 2026 7:20 AM
Business Wire
Synthesis of structurally complex and highly-engineered protein sequences to enable acceptance of approximately 99.5% of clonal gene orders and 99.9% of all DNA products


Complex synthesis capabilities to support further advancement of AI-enabled drug discovery and nucleic acid therapeutics


Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes.


“As research in nucleic acid therapeutics and AI-guided protein design and therapeutics discovery accelerate, scientists need a reliable partner to consistently deliver genes rapidly at scale and with more complex sequences,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “At Twist we already had the speed, scale and cost advantage. Now, we’ve added complex sequences to our gene synthesis offering and expanded our length up to 7,000 base pairs. With reliable complexity at scale, we expect to be able to accept about 99.5% of clonal genes sequences sent to us by our customers and 99.9% of all DNA products, making Twist their one-stop-shop, whether they’re ordering straightforward constructs or highly challenging sequences, enabling faster iteration and accelerated discovery timelines for our customers.”


Sequences with complex elements have historically been difficult to produce at commercial scale. Leveraging its proprietary silicon-based DNA synthesis platform and improved downstream processes in manufacturing, automation, and sequencing, Twist can now reliably synthesize and deliver these previously out-of-reach complex sequences at scale. Complex sequence elements such as short tandem, inverted and long repeats, as well as high or low GC content and more, can be essential components of customers’ sequences in the development of nucleic acid therapeutics such as cell and gene therapies, mRNA therapies and more. The ability to synthesize complex sequences is also essential for AI-enabled drug discovery where researchers need their AI-generated sequences manufactured exactly, without adding a step to alter the sequences for manufacturability. By delivering genes with novel and complex structures combined with a transparent online ordering and tracking process, Twist enables customers to advance cutting edge research, empowering the development of new and next-generation therapeutics.


About Twist Complex Genes


Twist can synthesize and deliver complex sequences including short tandem repeats, inverted repeats, long repeats, homopolymers up to 30 base pairs and localized regions of high or low GC content. These are features commonly found in sequence elements such as advanced promoters, UTRs, ITRs, secondary structures and GS linkers. When customers submit sequences, they will receive a complexity score and a manufacturability score, for full transparency during the ordering process. Twist reliably delivers constructs ranging from 300 to 7,000 base pairs within 15 business days standard turnaround time, regardless of order scale or complexity. All Twist Clonal Genes can be cloned into a Twist catalog vector, or an onboarded vector of the customer’s choice. Learn more here.


About Twist Bioscience Corporation


At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets.


We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal – more experiments, more iterations, more chances for remarkable discoveries.


Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all. For more information about our products and services, please visit www.twistbioscience.com.


Follow us on LinkedIn | X | YouTube | Instagram | Bluesky


Twist Bioscience Legal Notice Regarding Forward-Looking Statements


This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated performance and adoption of the Complex Genes offering, the potential utility of complex sequences in AI-enabled drug discovery and nucleic acid therapeutics, and expectations regarding delivery timelines and manufacturing reliability for complex sequences. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; the ability to integrate and leverage artificial intelligence and machine learning technologies to improve operational efficiency, product development, and customer solutions; the ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist’s costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; the ability to maintain and enforce intellectual property protection; uncertainty as to economic and market conditions and the impact of adverse economic conditions; and the ability to obtain financing when necessary. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist’s business in general, see Twist’s risk factors set forth in Twist’s Annual Report on Form 10-K for the year ended September 30, 2025 filed with the Securities and Exchange Commission (SEC) on November 17, 2025 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260504627436/en/
For Investors:

Angela Bitting

SVP, Corporate Affairs

925-202-6211

abitting@twistbioscience.com


For Media:

Amanda Houlihan

Communications Manager

774-265-5334

ahoulihan@twistbioscience.com


Original: Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

Twist Bioscience shares jump 5% after revenue tops forecasts and outlook is liftedFebruary 2, 2026 9:51 AM
IH Market News
Twist Bioscience Corporation (NASDAQ:TWST) reported fiscal first-quarter 2026 revenue that came in ahead of market expectations on Monday, prompting a rally in the stock, even though earnings fell short of forecasts.Shares of the biotech group were up about 5.16% in premarket trading following the announcement.Twist posted quarterly revenue of $103.7 million for the period ended December 31, 2025, beating the analyst consensus of $100.72 million and marking a 17% increase from $88.7 million a year earlier. The company, however, reported a net loss of $0.50 per share, wider than analysts’ expectations for a loss of $0.43 per share.Encouraged by the stronger-than-expected top-line performance, management raised its full-year fiscal 2026 revenue guidance to a range of $435 million to $440 million, up from the prior outlook of $425 million to $435 million. The company also reiterated its goal of reaching adjusted EBITDA breakeven by the fourth quarter.“We’re continuing to build on the momentum we established in fiscal 2025, starting the new fiscal year with our twelfth consecutive quarter of growth,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Revenue of $103.7 million exceeded guidance and increased 17% compared to the first quarter of 2025.”Profitability metrics also improved, with gross margin rising to 52.0% in the quarter, up roughly four percentage points from 48.3% in the same period last year. Twist shipped products to around 2,538 customers during the quarter, compared with 2,376 customers in the first quarter of fiscal 2025.Looking ahead, the company expects second-quarter revenue of approximately $107 million to $108 million, implying about 16% year-on-year growth. Twist also said it anticipates gross margin will remain above 52% for the full 2026 fiscal year.As of December 31, 2025, the company reported approximately $198 million in cash, cash equivalents and short-term investments.Twist Bioscience Corporation stock price

Original: Twist Bioscience shares jump 5% after revenue tops forecasts and outlook is lifted

Twist Bioscience Announces Fiscal 2026 First Quarter Financial ResultsFebruary 2, 2026 7:15 AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the first quarter fiscal 2026 ended December 31, 2025.


Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal first quarter 2026 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations.


The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company’s business. The conference call will be webcast live through the Investor Relations section under the “Company” tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.


About Twist Bioscience Corporation


At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.


Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit www.twistbioscience.com.


Follow us on LinkedIn | X | YouTube | Instagram | Bluesky

View source version on businesswire.com: https://www.businesswire.com/news/home/20260202309201/en/
For Investors:

Angela Bitting

SVP, Corporate Affairs

925-202-6211

abitting@twistbioscience.com


For Media:

Amanda Houlihan

Communications Manager

774-265-5334

ahoulihan@twistbioscience.com


Original: Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results

TWST, new 52/ week low

TWST, 10Q due Monday 5/5

TWST under $50

TWST is volatile but the trend remains bullish

TWST new 52 week high

TWST over $30

TWST new 52 week high

$TWST Markets down,,Twist is up!!

Twist Bioscience Corp NASDAQ: TWST

GoSymbol lookup
Health Care : Biotechnology | Small Cap GrowthCompany profile
Twist Bioscience Corporation is a synthetic biology company. The Company has developed a disruptive DNA synthesis platform. The core of its platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by writing DNA on a silicon chip. The Company utilizes its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for sample preparation and antibody libraries for drug discovery and development. The Company's product lines, synthetic biology tools and NGS tools, addresses different needs of its customers across a range of applications, such as synthetic genes, oligo pools, SARS-CoV-2 tools, and DNA libraries. Its synthetic biology products include Synthetic genes and gene fragments, Oligonucleotide, or Oligo pools for CRISPR gene editing. The NGS products are used for diagnostic tests for various indications like SARS-CoV-2.

TWST (own it)

That awful Cathie Wood has been buying

Twist shareholders who have held company stock since before December 13, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award at no cost to them whatsoever.

https://grabarlaw.com/the-latest/twist-bioscience-shareholder-investigation/

It is alleged, in several class actions, that the Company and certain of its officers overstated the commercial viability of Twist Bioscience’s synthetic DNA manufacturing technology while engaging in accounting fraud and using unsustainable pricing to inflate Twist Bioscience’s true financial condition and prospects.

Unlike a class action, brought on behalf of investors, a shareholder derivative action or demand is brought by a shareholder of a public company on behalf of and for the benefit of the company itself. In a derivative action, shareholders “step into the shoes” of the directors and officers of a company and bring litigation that the board would be unwilling to pursue on its own. Shareholder derivative litigation can recover damages back to the company for financial or reputational harm caused by the conduct of its insiders, and also can be used to improve the governance of public companies in order to guard against such harms in the future.

Yes

Do you still hold TWST shares?

It is hard to believe that 95% of the outstanding shares are owned by institutions!!!!! That only leaves 5% for the rest of us little people to fight over.... it is going to get very expensive, very quickly, to get in if you are not in already!!!!

This should be a good ride to be on!

Got in today. Twist chips can store 10,000x more data on a chip than any other technique. That’s just one of their revenue streams Second: They are storing data IN DNA now!! Not science fiction. Third: they have all the DNA sequences!! Why sell them!! They are going to be developing drugs for everything from covid to cancer. Adding n dips. Good luck to all.

nice run-up for TWST this last year...looks like it went too high, panic sale today chopped all that gain...

Synthetic DNA Technology is gonna Change the World as we know it!!



$$TWST

Rumor from the yacht rock bands docking at The Canery is we’re $40 we tap this week.

$30 is the Support Level for TWST

I'm new here with TWST! Is TWST in a court battle??

Any proof of this??

What's pending here!!??

Good Company Here!!

Less than 9,000 shares traded all day so far? And lost 71 million on 25 million revenues last year? This company has a long ways to go to convince investors they are a viable alternative to the multitude of other investments out there. Somebody convince me otherwise. Please?

I think TWST could pull a TLRY, it definetly has the MOMO.

Ilumina bought Pacific biosciences recently for 1.2 billion. I believe TWST is already a buyout target for the big boys.

Great call observer21. I think were looking at a buyout when the lawsuit problems are settled.

Now that I've had more time to do due diligence, I'm more cautious. "Ginkgo Bioworks also accounted for 40% and 32% of our revenue for the nine months ended June 30, 2017 and 2018, respectively." ....Negative gross margins. ....and IR was unhelpful and dismissive of my questions...A vibe I personally cannot ignore. Entirely possible they were just having a bad day.
Good DD.... https://www.nanalyze.com/2018/10/twist-bioscience-stock-ipo/

Anyone have any knowledge concerning the Agilent lawsuit...timelines, Etc?

This company could be a blockbuster. Very exciting technology and a first mover.